This clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Patient has provided written informed consent
Patient is >18 years of age at the time of consent
Patient has a documented diagnosis of MM according to the IMWG diagnostic criteria (Appendix 1)
Measurable extramedullary disease by any imaging modality (at least one site of disease ≥1cm that has never received radiotherapy or has progressed following radiotherapy). Presence of biochemical measurable disease is not required
Known nickel or Pd sensitivity
Weight >105 Kg and/or height >185 cm
Known claustrophobia
Prior treatment with CAR-T therapy directed at any target
Peter MacCallum Cancer Centre, Australia
Lead sponsor
Janssen, LP
Collaborator